Related Experiment Video
Updated: Aug 11, 2026
07:04
Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
Published on: February 11, 2017
Gene therapy for cystic fibrosis
1National Heart & Lung Institute, Imperial College, Ion Transport Unit, Manresa Road, London SW3 6LR, UK. e.alton@ic.ac.uk
Expert Opinion on Investigational Drugs
|November 4, 2000
Summary
Gene therapy for cystic fibrosis (CF) shows promise but faces challenges. Research now focuses on overcoming airway barriers for effective DNA delivery and potential CF treatments.
Area of Science:
- Medical Genetics
- Pulmonary Medicine
- Biotechnology
Background:
- The identification of the cystic fibrosis gene in 1989 spurred optimism for gene therapy in genetic diseases.
- Early gene therapy efforts for cystic fibrosis targeted the lungs due to accessibility, but faced significant hurdles.
Purpose of the Study:
- To review the progress and challenges in developing gene therapy for cystic fibrosis.
- To highlight current research directions aimed at improving gene delivery efficiency for cystic fibrosis treatment.
Main Methods:
- Review of Phase I clinical safety trials for cystic fibrosis gene therapy conducted in the 1990s.
- Analysis of research findings on the barriers to gene transfer agents in the lung airway surface.
Main Results:
- Phase I trials demonstrated the safety of both viral and non-viral DNA delivery methods for cystic fibrosis.
- These early trials provided proof of concept but did not achieve clinical efficacy.
Conclusions:
- The airway surface acts as a significant barrier to topical gene transfer agents in cystic fibrosis.
- Future cystic fibrosis gene therapy research must address these delivery barriers to achieve clinical success.
Related Concept Videos
00:49What is Genetic Engineering?
Overview
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
01:23Cystic Fibrosis: Pathogenesis
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Microorganisms in Medicine and Therapeutics
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.